EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.923
https://www.valueinhealthjournal.com/article/S1098-3015(23)04053-6/fulltext
Title :
EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04053-6&doi=10.1016/j.jval.2023.09.923
First page :
Section Title :
Open access? :
No
Section Order :
10417